Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Radsak

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
The Lancet. Oncology|September 6, 2017
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension studyUwe Platzbecker, Ulrich Germing, Katharina S Götze, et al.
Clinical Chemistry and Laboratory Medicine|May 11, 2023
One fits all: a highly sensitive combined ddPCR/pyrosequencing system for the quantification of microchimerism after hematopoietic and solid organ transplantationFriederike Häuser, Jens Mittler, Misra Simge Hantal, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 3, 2013
Mast cell-deficient Kit(W-sh) "Sash" mutant mice display aberrant myelopoiesis leading to the accumulation of splenocytes that act as myeloid-derived suppressor cellsAnastasija Michel, Andrea Schüler, Pamela Friedrich, et al.
EXCLI Journal|February 28, 2022
Hypermethylation of <i>RAD9A</i> intron 2 in childhood cancer patients, leukemia and tumor cell lines suggest a role for oncogenic transformationDanuta Galetzka, Julia Böck, Lukas Wagner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 23, 2022
Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS StudyUwe Platzbecker, Katharina S Götze, Philipp Kiewe, et al.
Hemasphere|April 25, 2023
Identification of Adult Patients With Classical Dyskeratosis Congenita or Cryptic Telomere Biology Disorder by Telomere Length Screening Using Age-modified CriteriaMareike Tometten, Martin Kirschner, Robert Meyer, et al.
The Lancet. Oncology|June 9, 2019
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trialJorge E Cortes, Samer Khaled, Giovanni Martinelli, et al.
Blood Advances|February 12, 2025
Late-onset telomere biology disorders in adults: clinical insights and treatment outcomes from a retrospective registry cohortMareike Tometten, Fabian Beier, Martin Kirschner, et al.
Science (New York, N.Y.)|March 12, 2021
Lipid presentation by the protein C receptor links coagulation with autoimmunityNadine Müller-Calleja, Anne Hollerbach, Jennifer Royce, et al.
The Journal of Clinical Investigation|July 2, 2026
Extracellular matrix reprogramming by the YAP/TAZ- TGF-ß2 axis drives immune exclusion in cholangiocarcinoma modelsMarco Jessen, KyungMok Kim, Marie Tollot-Wegner, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
The Lancet. Oncology|September 6, 2017
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension studyUwe Platzbecker, Ulrich Germing, Katharina S Götze, et al.
Clinical Chemistry and Laboratory Medicine|May 11, 2023
One fits all: a highly sensitive combined ddPCR/pyrosequencing system for the quantification of microchimerism after hematopoietic and solid organ transplantationFriederike Häuser, Jens Mittler, Misra Simge Hantal, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 3, 2013
Mast cell-deficient Kit(W-sh) "Sash" mutant mice display aberrant myelopoiesis leading to the accumulation of splenocytes that act as myeloid-derived suppressor cellsAnastasija Michel, Andrea Schüler, Pamela Friedrich, et al.
EXCLI Journal|February 28, 2022
Hypermethylation of <i>RAD9A</i> intron 2 in childhood cancer patients, leukemia and tumor cell lines suggest a role for oncogenic transformationDanuta Galetzka, Julia Böck, Lukas Wagner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 23, 2022
Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS StudyUwe Platzbecker, Katharina S Götze, Philipp Kiewe, et al.
Hemasphere|April 25, 2023
Identification of Adult Patients With Classical Dyskeratosis Congenita or Cryptic Telomere Biology Disorder by Telomere Length Screening Using Age-modified CriteriaMareike Tometten, Martin Kirschner, Robert Meyer, et al.
The Lancet. Oncology|June 9, 2019
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trialJorge E Cortes, Samer Khaled, Giovanni Martinelli, et al.
Blood Advances|February 12, 2025
Late-onset telomere biology disorders in adults: clinical insights and treatment outcomes from a retrospective registry cohortMareike Tometten, Fabian Beier, Martin Kirschner, et al.
Science (New York, N.Y.)|March 12, 2021
Lipid presentation by the protein C receptor links coagulation with autoimmunityNadine Müller-Calleja, Anne Hollerbach, Jennifer Royce, et al.
The Journal of Clinical Investigation|July 2, 2026
Extracellular matrix reprogramming by the YAP/TAZ- TGF-ß2 axis drives immune exclusion in cholangiocarcinoma modelsMarco Jessen, KyungMok Kim, Marie Tollot-Wegner, et al.
Pageof 4